Therapeutics News and Research

RSS

The Native Antigen Company launches ground-breaking Zika virus immunoassays

The Native Antigen Company has launched a series of ground-breaking immunoassays for Zika virus, offering researchers in academia, public health and drug discovery the capability to work with unprecedented levels of specificity and sensitivity.

29 Nov 2018

Report recommends creation of health monitoring, research program on Gulf War and post-9/11 veterans

To help determine if the descendants of Gulf War and post-9/11 veterans are at risk for health effects resulting from the service members' exposure to toxicants during deployment, a new report from the National Academies of Sciences, Engineering, and Medicine recommends the creation of a health monitoring and research program.

29 Nov 2018

New study solves longstanding mystery in innate immunity

UT Southwestern biochemist and Breakthrough Prize winner Dr. Zhijian "James" Chen's newest study answers a long-standing question in the field of innate immunity.

29 Nov 2018

Toxicologists and pharmacologists meet at international conference in Adelaide

Experts will meet to discuss the latest discoveries in drugs and how best to use existing ones as effectively and safely as possible, at an international conference in Adelaide this week (27-30 November).

27 Nov 2018

Using big data to hack the aging code

Aging is the most important single factor behind chronic diseases and death. As "silver tsunami" approaches, healthcare and social protection systems face the looming crisis.

27 Nov 2018

Scientists identify key component of microscopic machinery that drives cell death

An important component of the microscopic machinery that drives cell death has been identified by Walter and Eliza Hall Institute scientists.

27 Nov 2018

BIO issues statement on proposed changes to Medicare Part D and Medicare Advantage plans

BIO President and CEO Jim Greenwood issued the following statement regarding today's proposed changes to Medicare Part D and Medicare Advantage plans.

26 Nov 2018

NIH-funded study finds how hantaviruses infect the lungs

A human protein associated with asthma is key to how hantaviruses infect the lungs and sometimes cause a life-threatening pulmonary condition known as hantavirus pulmonary syndrome, according to researchers supported by the National Institutes of Health.

26 Nov 2018

GE Healthcare showcases new Edison applications and Edison-powered devices at RSNA 2018

GE Healthcare today announced new applications and smart devices built on Edison - a platform that helps accelerate the development and adoption of Artificial Intelligence technology and empower providers to deliver faster, more precise care.

25 Nov 2018

New method enhances efficiency and accuracy of single cell RNA sequencing

In the era of personalized medicine, scientists are using new genetic and genomic insights to help them determine the best treatment for a given patient. In the case of cancer, the first step toward these treatments is an investigation into how tumor cells behave in an effort to figure out the best drugs to use to attack them.

22 Nov 2018

Scientists identify key protein involved in Hantavirus Pulmonary Syndrome

A global team of investigators has identified a key protein involved in Hantavirus Pulmonary Syndrome, a serious and sometimes fatal respiratory disease, according to research published today in the journal Nature.

22 Nov 2018

Peanut allergies could soon have a drug treatment

Millions of individuals worldwide suffer from peanut allergies. Researchers are developing a new treatment for fighting this allergy. A clinical trial had been conducted and the results are in.

20 Nov 2018

Researchers shed light on molecular mechanisms of heart valvular disease

About three per cent of the world's population is affected by valvular heart diseases. It is also the most common cause of heart surgery, as no drug-based treatment is available.

20 Nov 2018

Location matters for inflammation clearance

Health conditions that involve inflammation run the gamut, from multiple sclerosis and lupus to arthritis, diabetes, and cancer. While inflammation can serve as a normal response to help the body deal with injury or infection, problems arise when it persists, potentially harming surrounding tissues.

20 Nov 2018

New drug shows promise for treating people with peanut allergy

Controlled ingestion of peanut protein could help build tolerance in peanut allergy sufferers. Authors of a new study published in the New England Journal of Medicine say an oral immunotherapy drug they tested could be the first FDA-approved medication of its kind for people with peanut allergy.

19 Nov 2018

RNAi therapy shown to alleviate preeclampsia in animal model

Researcher have used a small interfering RNA (siRNA) to reduce preeclampsia symptoms in an animal model. The approach could provide a new way of treating preeclampsia in humans.

19 Nov 2018

New model of FSHD could be useful to study effectiveness of experimental therapeutics

Facioscapulohumeral muscular dystrophy is the most prevalent dominantly inherited muscular dystrophy in the world. To date, there are no pharmacologic treatments available for the more than 850,000 people affected worldwide.

17 Nov 2018

New method to analyze cell membrane complexes could revolutionize the way we study diseases

Researchers have developed a new technique to analyze cell membrane proteins in situ which could revolutionize the way in which we study diseases, such as cancer, metabolic and heart diseases.

17 Nov 2018

Researchers awarded $10 million grant to address root causes of asthma in Puerto Rico

Researchers at the University of California, San Francisco, National Jewish Health and Centro de Neumología Pediátrica in Puerto Rico have been awarded nearly $10 million as part of a 5-year grant from the U.S. National Heart Lung and Blood Institute, part of the National Institutes of Health, to address the root causes of asthma by studying 4,000 children in Puerto Rico, where asthma prevalence and deaths are among the highest in the world.

16 Nov 2018

Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10 mg per 10 mL vial for injection.

16 Nov 2018